Introduction {#S1}
============

Hormonal physiology plays an important role in the function of the prostate. Development, growth, and functions of this gland depend on the actions of testosterone and its metabolite dihydrotestosterone (DHT), which enable the growth and proliferation of the glandular component of the prostate through binding and activation of androgen receptor (AR) within the cytoplasm of prostatic epithelial cells ([@B1]). In contrast to the chemical and virus-induced tumors, the hormone-related cancers shared a quite different mechanism of carcinogenesis: hormones, both endogenous and exogenous, drive cell proliferation, increasing the number of cell divisions and the opportunity for random genetic errors ([@B2]--[@B4]). In some cases, hormones can be metabolized to genotoxic agents by enzymes, which can form adducts with DNA and lead to mutations ([@B5]). The actions of androgen hormones are very controversial in prostatic hyperplasia \[benign prostate hypertrophy (BPH)\] and prostate cancer (PCa). Several studies showed that the activation of AR results in proliferative growth of prostatic epithelium, favoring the transition from prostatic hyperplasia (BPH) to PCa ([@B4], [@B6], [@B7]). However, lower levels of testosterone and DHT are associated with BPH and PCa ([@B8]--[@B11]). As men age, the free serum testosterone declines by 2--3% approximately annually ([@B12]); yet, there is increase in the incidence of BPH, and longevity increases the number at risk. Also, men who have high body mass index have larger prostates but lower testosterone levels ([@B13]). There is a potential explanation of lower levels of testosterone and DHT with BPH, as explained through a murine model where the authors blocked AR activation in the luminal cells, leading to inflammation of the prostate gland in these animals ([@B14]). Inflammation and subsequent angiogenesis lead to PCa progression ([@B15]), and we identified a fragment of complement C3f in low prostate-specific antigen (PSA) samples ([@B16]). PSA is a specific prostate marker, but only marginally influences mortality from PCa, and a recent study of the available PCa biomarkers suggested more candidate biomarkers ([@B17]).

Most of the studies measuring testosterone and DHT (cited above) used immunoenzymatic (ELISA) and radioimmuno-assay (RIA) to measure total testosterone, then applied Vermeulen's formula (based on sex hormone-binding globulin and albumin) to calculate free testosterone. Analysis of testosterone in serum is quite complicated, especially in ELISA and RIA conditions, where the low amount and enzymatic cross-reactions seriously affect their quantitation ([@B18]). Recently, mass spectrometry (MS) has been elected as the reference technology for steroid dosage ([@B19]--[@B23]) since the sensitivity and specificity of this technology avoids the quantification problems in ELISA and RIA conditions. Steroids dosage also represents a crucial task for the diagnosis of different diseases ([@B22], [@B24]--[@B27]), such congenital adrenal hyperplasia ([@B28]), cardiovascular ([@B22]), and other degenerative diseases ([@B24], [@B26], [@B27]).

Liquid chromatography tandem MS operating in multiple reaction monitoring conditions (LC-MS/MS-MRM) is actually the most employed technology for steroids analyses ([@B23], [@B29]). Different methods have been developed in both electrospray (ESI) ([@B30]) and Atmospheric Pressure Ionization conditions (APCI) ([@B31]) combined to triple quadrupole (QQQ) as mass analyzer ([@B32]). QQQ has gained the consensus of clinical institutes mainly due to its higher quantitation accuracy in target analysis with respect to other analyzers ([@B29], [@B32]).

In addition to quantification of steroids by LC-MS/MS, other investigations show that the clinical information correlated with the disease is not only contained in the absolute steroid quantitation, but rather in their ratios ([@B33], [@B34]). This reflects their synthesis starting from the precursor cholesterol and the enzymes involved (Figure [S1](#SM1){ref-type="supplementary-material"} in Supplementary Material). For example, a deficit in 21-hydroxylase leads to a decrease in mineralocorticoids and glucocorticoids and to an increase of androgens and testosterone ([@B4]). Thus, the ratio can be an informative and complementary diagnostic tool.

Surface Activated Chemical Ionization-Electrospray-NIST Bayesian model database search (SANIST) platform has been recently proposed by us as a powerful tool for personalized medicine ([@B28], [@B35]). Basically, it is an open platform based on three core points: (a)Standardized kits for sample preparation to maximize the inter-laboratory data reproducibility.(b)Use of SACI/ESI ionization source to reduce the instrument chemical noise and increase the number of detectable analytes.(c)The SANIST data elaboration technology that is based on an open model: different applications are progressively added depending to the analysis target.

Concerning the point (c) SANIST has been currently implemented with two applications: (a)An application to be used for biomarker discovery, able to classify samples and diagnose diseases on the basis of Bayesian machine learning approach ([@B35]). This technology makes possible to consider the individual variability and correct the diagnose bias obtained using fixed biomarkers ([@B36], [@B37]).(b)An application to identify the analytes in conformity with the guidelines suggested by the European Community (EU directive 2002/657/EC) ([@B35]).

We describe here the development and application of a new SANIST platform to quantify steroids for diagnostic purposes going toward a personalized medicine approach. In detail, 10 steroids \[aldosterone, corticosterone, cortisol, 11-deoxycortisol, androstenedione, testosterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), 17-OH-progesterone and progesterone\] have been quantitatively detected by means of SANIST technology and their profile has been analyzed for PCa diagnosis. The profiles of 71 serum samples (31 controls, 20 patients with PCa, and 20 subjects with benign prostate hyperplasia) were evaluated. The ability of the steroids profiling to discriminate among the different groups was tested both considering the individual percent concentration and the relative ratio relationships, showing that the predictive performances are better when using the relative relationship conditions.

Materials and Methods {#S2}
=====================

Chemicals {#S2-1}
---------

A CE-IVD certified and standardized kit for steroids analysis was purchased from ISBN (Varese, Italy). The kit contains LC mobile phases (phases A and B), the sample precipitation reagent E and the sample resuspension reagent D. Aldosterone, Corticosterone, Cortisol, 11-deoxycortisol, Androstenedione, Testosterone, DHEA, DHEAS, 17-OH-Progesterone and Progesterone standards were purchased from (ISBN laboratory, Varese, Italy) together with their internal standard (Aldosterone d~8~, Androstenedione ^13^C~3~, Corticosterone d~4~, Cortisol d~4~, 11-Deoxycortisol d~5~, DHEA d~6~, Progesterone ^13^C~3~, 17-OH-Progesterone ^13^C~3~, DHEAS d~6~, Testosterone ^13^C~3~). Analyte controls at defined concentrations were purchased from (ISBN laboratory, Varese, Italy). Table [S1](#SM3){ref-type="supplementary-material"} in Supplementary Material reports the internal standard concentrations while Table [S2](#SM4){ref-type="supplementary-material"} in Supplementary Material has the known calibrate analyte concentrations and the calculated concentrations of both known and unknown samples.

Sample Selection, Collection, and Preparation {#S2-2}
---------------------------------------------

Samples were selected among 50-year-old male patients being subjected to a prostate biopsy for PCa diagnosis at the Urology Unit of the MultiMedica Castellanza, Varese, Italy, without considering those affected by autoimmune diseases, hypersensitivities, and other immune-mediated physical states. Multiple serum PSA analyses were performed on patients along with digital rectal exam and ultrasound. Many different clinical parameters were used to classify patients among which the histological analysis of the biopsy, total PSA, free-PSA, PSA-velocity (changes in PSA levels over time), ultrasound and rectal analysis. Controls included healthy subjects undergoing PSA dosage at our Urology unit that had a PSA lower than 2.5 ng/mL (28 patients) or less than 4 ng/mL and free PSA greater than 15% (3 patients). The study was approved by the institutional review board ethics committee (Protocol N 10 2 10/2011) and, according to the Helsinki Declaration of 1975 as revised in 2013, informed consent was provided by all patients. 71 serum samples (31 controls, 20 patients with PCa, and 20 subjects with benign prostate hyperplasia) were collected (sample number, age, PSA, AR positivity, and Gleason score are shown in Table [1](#T1){ref-type="table"}). Blood samples were treated to obtain sera: they were collected in siliconized tubes, left to coagulate for 30 min and then subjected to centrifuge for 30 min at 3,000 rpm at 4°C to reduce variability through the collection of the samples ([@B38]). 1.8-mL cryotube vials (Thermo Fisher Scientific, Rodano, Milan, Italy) were used to collect sera and store them at −80°C until the time of analysis. 10 µL of steroids isotopically labeled internal standard at known concentration (Table [S1](#SM3){ref-type="supplementary-material"} in Supplementary Material) were added to 290 µL of serum to normalize them. 600 µL of precipitating reagent E were added to each sample. They were then centrifuged for 1 min at 13,000 × *g*/min using a (Biospin, Eppendorf, Germany). 700 µL of the supernatant were collected in another Eppendorf tube and dried with nitrogen gas. The dried pellet was resuspended using 70 µL of reagent D. The analyte calibrants (Table [S2](#SM4){ref-type="supplementary-material"} in Supplementary Material) were treated with the same procedure employed for the sample preparation. Quantitative analysis stability was checked by inserting standard controls at different known concentrations enclosed in the kit employed for the dosage (Table [S1](#SM3){ref-type="supplementary-material"} in Supplementary Material). Limit of detection (LOD) and quantitation (LOQ) were calculated using the standard calibration curves (7 points).

###### 

Clinical characteristics of the (a) patients, (b) Benign prostate hypertrophy, and (c) controls subjects.

  1A. Patients                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ------------------------------------- ----------------------------- ------------------- ----------------------- ---------------------------------------------------------------------------- ------------------------------------------ ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------------
  A0001                                 58                            7 (3 + 4)           \>95                    6.00                                                                         1,144.79                                   44.5                                                                         Benign prostate hypertrophy (BPH)/HC                                         BPH/HC                                       PCa
  A0003                                 78                            8 (4 + 4)           \>95                    43.00                                                                        191.792                                    49.3                                                                         PCa                                                                          PCa                                          PCa
  A0004                                 66                            7 (3 + 4)           \>95                    8.00                                                                         591.168                                    38.7                                                                         PCa                                                                          PCa                                          PCa
  A0005                                 68                            7 (3 + 4)           \>95                    9.50                                                                         638.852                                    49.8                                                                         PCa                                                                          PCa                                          PCa
  A0006                                 76                            6 (3 + 3)           \>95                    7.30                                                                         385.659                                    42.2                                                                         BPH/HC                                                                       PCa                                          PCa
  A0007                                 82                            7 (4 + 3)           \>95                    78.00                                                                        2,106.52                                   42.7                                                                         PCa                                                                          BPH/HC                                       PCa
  A0008                                 74                            7 (3 + 4)           \>95                    5.29                                                                         1,490.21                                   51.1                                                                         BPH/HC                                                                       BPH/HC                                       PCa
  A0010                                 70                            7 (4 + 3)           \>95                    400.00                                                                       234.102                                    52.9                                                                         PCa                                                                          PCa                                          PCa
  A0011                                 80                            6 (3 + 3)           \>95                    11.00                                                                        247.311                                    47.6                                                                         PCa                                                                          PCa                                          PCa
  A0012                                 69                            6 (3 + 3)           \>95                    10.00                                                                        430.209                                    49.3                                                                         PCa                                                                          PCa                                          PCa
  A0014                                 70                            6 (3 + 3)           \>95                    12.00                                                                        903.685                                    40.9                                                                         PCa                                                                          BPH/HC                                       PCa
  A0015                                 78                            7 (3 + 4)           \>95                    4.90                                                                         294.322                                    50.2                                                                         BPH/HC                                                                       PCa                                          PCa
  A0017                                 72                            6 (3 + 3)           \>95                    12.00                                                                        1,286.50                                   52.0                                                                         PCa                                                                          BPH/HC                                       PCa
  A0018                                 69                            7 (3 + 4)           \>95                    ND                                                                           1,423.28                                   5.0                                                                                                                                                       BPH/HC                                       HC
  A0020                                 61                            7 (4 + 3)           \>95                    5.52                                                                         553.783                                    8.0                                                                          BPH/HC                                                                       PCa                                          HC
  A0021                                 75                            6 (3 + 3)           \>95                    5.50                                                                         519.083                                    43.1                                                                         BPH/HC                                                                       PCa                                          PCa
  A0022                                 65                            7 (3 + 4)           \>95                    21.00                                                                        1,209.71                                   47.1                                                                         PCa                                                                          BPH/HC                                       PCa
  A0023                                 56                            7 (3 + 4)           \>95                    6.29                                                                         977.112                                    47.6                                                                         BPH/HC                                                                       BPH/HC                                       PCa
  A0024                                 57                            9 (4 + 5)           \>95                    12.00                                                                        1,142.33                                   51.6                                                                         PCa                                                                          BPH/HC                                       PCa
  A0025                                 72                            7 (3 + 4)           \>95                    8.70                                                                         168.51                                     44.9                                                                         PCa                                                                          PCa                                          PCa
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **1B. Benign prostate hypertrophy**                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Benign prostate hypertrophy**       **Classification based on**                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **ID**                                **Age**                       **Gleason score**   **Androgen receptor**   **Total PSA**                                                                **DHEAS**                                  **Relationship average ratio discriminating coefficient (relative value)**   **PSA[^a^](#tfn1){ref-type="table-fn"}**                                     **DHEAS[^b^](#tfn2){ref-type="table-fn"}**   **Relationship average ratio discriminating coefficient (relative value)**
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C0001                                 57                                                \>95                    5.20                                                                         1,443.20                                   22.6                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0002                                 64                                                \>95                    17.00                                                                        947.786                                    19.6                                                                         PCa                                                                          BPH/HC                                       BPH
  C0003                                 65                                                \>95                    7.27                                                                         1,158.89                                   21.6                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0004                                 75                                                \>95                    9.12                                                                         317.604                                    26.8                                                                         PCa                                                                          PCa                                          BPH
  C0005                                 64                                                \>95                    11.00                                                                        1,550.66                                   22.8                                                                         PCa                                                                          BPH/HC                                       BPH
  C0007                                 62                                                \>95                    5.45                                                                         1,590.28                                   44.3                                                                         BPH/HC                                                                       BPH/HC                                       PCa
  C0008                                 66                                                \>95                    4.68                                                                         684.52                                     48.9                                                                         BPH/HC                                                                       PCa                                          PCa
  C0009                                 61                                                \>95                    5.40                                                                         955.398                                    23.5                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0010                                 63                                                \>95                    2.50                                                                         1,508.79                                   18.7                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0012                                 59                                                \>95                    5.80                                                                         2,363.96                                   47.4                                                                         BPH/HC                                                                       BPH/HC                                       PCa
  C0014                                 60                                                \>95                    6.00                                                                         2,216.43                                   50.3                                                                         BPH/HC                                                                       BPH/HC                                       PCa
  C0016                                 54                                                \>95                    5.50                                                                         1,622.97                                   23.5                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0017                                 58                                                \>95                    6.60                                                                         584.228                                    18.9                                                                         BPH/HC                                                                       PCa                                          BPH
  C0018                                 58                                                \>95                    12.94                                                                        600.57                                     18.9                                                                         PCa                                                                          PCa                                          BPH
  C0019                                 52                                                \>95                    10.33                                                                        1,552.22                                   20.3                                                                         PCa                                                                          BPH/HC                                       BPH
  C0020                                 50                                                \>95                    3.54                                                                         899.207                                    23.9                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0021                                 69                                                \>95                    6.00                                                                         901.446                                    26.4                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0022                                 63                                                \>95                    6.00                                                                         1,300.37                                   21.4                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0023                                 52                                                \>95                    5.44                                                                         1,844.59                                   21.9                                                                         BPH/HC                                                                       BPH/HC                                       BPH
  C0024                                 62                                                \>95                    8.94                                                                         911.52                                     24.4                                                                         PCa                                                                          BPH/HC                                       BPH
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **1C. Controls subjects**                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Healthy controls**                  **Classification based on**                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **ID**                                **Age**                       **Total PSA**       **DHEAS**               **Relationship average ratio discriminating coefficient (relative value)**   **PSA[^a^](#tfn1){ref-type="table-fn"}**   **DHEAS[^b^](#tfn2){ref-type="table-fn"}**                                   **Relationship average ratio discriminating coefficient (relative value)**                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  HC0001                                79                            1.11                907.043                 5.3                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0002                                54                            0.5                 1,672.22                5.3                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0003                                72                            1.12                538.336                 4.5                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0004                                84                            ND                  298.8                   6.4                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0005                                64                            0.45                1,512.15                49.5                                                                                                                    BPH/HC                                                                       PCa                                                                                                                       
  HC0006                                54                            1.66                531.844                 47.4                                                                                                                    PCa                                                                          PCa                                                                                                                       
  HC0007                                60                            1.91                1,853.55                6.0                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0008                                50                            0.24                1,848.17                5.7                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0009                                83                            1.23                1,680.05                48.6                                                                                                                    BPH/HC                                                                       PCa                                                                                                                       
  HC0010                                54                            0.33                2,534.77                5.8                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0011                                66                            1.13                960.77                  6.2                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0012                                57                            1.2                 1,440.51                5.6                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0013                                73                            0.5                 1,167.40                5.4                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0014                                78                            2.53                673.551                 49.7                                                                                                                    PCa                                                                          PCa                                                                                                                       
  HC0015                                70                            0.43                602.138                 6.1                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0016                                65                            0.43                1,438.50                5.6                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0017                                59                            0.24                844.584                 5.8                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0018                                65                            1.94                1,678.04                4.6                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0019                                58                            1.85                1,440.07                6.3                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0020                                67                            2.81                1,377.38                47.6                                                                                                                    BPH/HC                                                                       PCa                                                                                                                       
  HC0021                                55                            3.16                1,419.92                4.3                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0022                                66                            1.79                530.501                 4.5                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0023                                72                            1.99                541.246                 5.1                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0024                                71                            1.21                534.53                  48.7                                                                                                                    PCa                                                                          PCa                                                                                                                       
  HC0025                                68                            1.1                 627.21                  6.1                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0026                                82                            0.71                1,408.50                6.1                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0027                                60                            0.63                1,988.76                6.1                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0028                                54                            1.22                193.359                 4.6                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0029                                54                            0.42                1,037.78                6.0                                                                                                                     BPH/HC                                                                       HC                                                                                                                        
  HC0030                                79                            1.46                430.433                 4.8                                                                                                                     PCa                                                                          HC                                                                                                                        
  HC0031                                84                            1.49                1,128.00                4.7                                                                                                                     BPH/HC                                                                       HC                                                                                                                        

*^a^Based on the lower limit of the 95 CI of the geometric mean of PCa patients (7.385)*.

*^b^Based on the upper limit of the 95 CI of the geometric mean of PCa patients (888.7)*.

Chromatography {#S2-3}
--------------

To study the selected analytes, a NeXera UPLC liquid chromatography apparatus (Shimatzu, San Jose, CA, USA) was employed. A Hypersylgold C18 2.1 mm × 50 mm 1.8 µm column was used. The ISBN kit has two mobile phases that were employed (Phases A and B). The LC apparatus worked in a binary gradient: 5% of B was kept for 0.5 min, after 3.5 min, B was increased to 45%, after other 8 min, B was raised to 65% and in 0.1 min to 100%. This percent was maintained for 1.9 min, then, 5% of B was achieved in 0.1 min and the column equilibrium was re-established reaching the starting conditions for 2.9 min. The total time of the analysis was 17 min. A 0.55 mL/min chromatographic flow was employed with a 20 µL injection volume.

Mass Spectrometry {#S2-4}
-----------------

Molecule assessments were achieved using 120 series triple quadrupole (PerkinElmer, USA) operating in SANIST mode. Heated SACI-ESI capillary had a 1,500 V voltage, SACI-ESI surface had a 47 V voltage, dry gas was kept to 2 L/min, 80 psi Nebulizer, and 40°C temperature were set. Collision-induced dissociation conditions were established for tandem MS experiments using Ar as the collision gas. The first quadrupole had an isolation window of ±0.3 *m/z* and the second one of 0.1 *m/z*.

Spectra Stability Evaluation {#S2-5}
----------------------------

Chromatographic peak spectral average was performed to obtain the higher spectrum quality. Only signal intensities higher than 10^3^ counts/s were considered to improve the spectrum quality.

General Normalization {#S2-6}
---------------------

As a normalization factor, since the concentrations of cortisol and DHEAS were far above any of the other steroid values, they were reduced by dividing 10 and 100 times, respectively.

SANIST Data Elaboration Platform {#S2-7}
--------------------------------

The disease classification among controls, PCa, and subjects with benign prostate hyperplasia were obtained using two approaches: (a) singular absolute concentration match and (b) steroid ratio relationship match (Figure [S2](#SM2){ref-type="supplementary-material"} in Supplementary Material). The SANIST tool acquires the selected potential steroid quantitation value and calculates the different combinatorial concentration ratio values. The steroids concentration ratio relationships are processed with the novel Bayesian data analysis-based SANIST mathematical model. SANIST data elaboration system calculates the probability that the detected steroid profile was associated to known disease (e.g., PCa). Biomarker profiles of serum from biopsy positive (PCa) and negative (BPH) subjects were analyzed and inserted to previously instruct the system. The probability in which an event occurs is determined by the Bayes' theorem. Based on this interpretation, Bayes' theorem is defined as the relationship between P(A) (probability that an acquired profile matches a PCa patient), P(B) (probability that a "fingerprint" biomarker profile corresponds to a biopsy negative subject), P(A \| B) and P(B \| A) for any events considering A and B in the same event space. In our case A and B indicate the different steroid concentration ratios. Following the Bayesian interpretation, probability, or uncertainty measures the confidence that something is true. Under this theory, Bayes' theorem relates uncertainty before and after observing proof. The initial uncertainty in A is the prior, P(A). The uncertainty having accounted for evidence B is the posterior, P(A \| B). The degree of support B provides for A is represented by the P(B \| A)/P(B) ratio. Formula [I](#E1){ref-type="disp-formula"} shows the relationship among the probabilistic function: $$\text{P}(\text{A|B})\text{=}\frac{\text{P}(\text{B|A})\text{P}(\text{A})}{\text{P}(\text{B})}$$

We introduced a new coefficient in formula ([I](#E1){ref-type="disp-formula"}) that gives formula ([II](#E2){ref-type="disp-formula"}): $$\text{P}(\text{A|B})\text{=}\frac{\text{P}(\text{B|A})\text{P}(\text{A})}{\text{P}(\text{B})} \ast C(mz,rt,i)$$

The correction factor *C* (*mz, rt, i*) enables to progressively rise the disease classification accuracy, on the basis of the number of uncorrected sample classification. In our case, the correct classification of the samples as PCa biopsy positive or negative with the SANIST tool. At least 10,000 sequential classification steps are required to reach this result. It is possible to evaluate the probability that the data observed in the serum are correctly classifiable with the theorem considering the steroid levels and different combinatorial concentration ratios.

We used two models for classification of the individual patient profiles: (a)Singular absolute concentration match. In this model, a vector database containing the analyte *m*/*z* ratio vs the singular analytes concentration and a percent value is obtained. The control, PCa, or benign prostate hyperplasia samples were classified, using the SANIST algorithm ([@B35]), by matching their concentration vector again the machine learning database excluding the identity match.(b)Steroids ratio relationships match. In this model, all the ratios of the concentration of the analyzed steroids are obtained and a vector of ratio index \[*R*(*i*)\] is obtained for each sample. The vector machine learning database is obtained by classifying each vector as a control, patient with PCa, or with benign prostate hyperplasia. Each subject was classified, using the SANIST algorithm ([@B39]), by similarity of its ratio vector versus the database by excluding the identity match.

SANIST Application for Steroids Relationship Calculation Spectral Matching Algorithm {#S2-8}
------------------------------------------------------------------------------------

SANIST proprietary data elaboration platform configuration has shown in a previous publication ([@B35]). SANIST application converts the sample amount in ratio index using the formula ([1](#E3){ref-type="disp-formula"}): $$\left. R(i,k)(k = \text{1~to~}(n - \text{1}))\lbrack(i = (k + \text{1})\text{~to~}(n)) \right\rbrack = C(k)/C(i + \text{1})$$

where *n* is the total number of analyte, *i* is an analyte counter, and *R* is the analyte concentration ratio given by the *C* concentration factor. The formula ([1](#E3){ref-type="disp-formula"}) is repeated for (*n* − 1) cycles so to calculate a number or *R*(*i*) ratio following the *k* index. The obtained ratios are employed in order to obtain a comparison vector with the (*k*;*i*) vs *R*(*i*;*k*). The number of *R* ratios depends on the number of analytes (*n*) and is given by the Eq. [2](#E4){ref-type="disp-formula"}. $$N(R)((k = \text{1~to~}( n - \text{1})) = \text{Sum~}(n - i)$$

SANIST Application for Steroid Singular Absolute Concentration Match {#S2-9}
--------------------------------------------------------------------

Classical data comparison was obtained by calculating the comparison vector considering the *m*/*z* vs C normalized (Cn) data. A *m*/*z* virtual parameter having a value of 1,000 was inserted in the vector as normalizing factor and its *C* value (Cv) was given by the sum of all the concentration parameters (see Eq. [3](#E5){ref-type="disp-formula"}): $$\text{Cv} = \text{Sum~}(i = \text{1~to~}n)\ (C\ i)$$

The Cn normalized data is calculated as a relative concentration with respect to Cv (Eq. [4](#E6){ref-type="disp-formula"}): $$\text{Cn} = (\text{Ci}/\text{Cv}) \ast \text{1}00$$

The final comparison vector is so given by *m*/*z* vs Cn pairs.

Results and Discussion {#S3}
======================

The LC-MS/MS-MRM data acquisition was optimized by monitoring the transitions reported in Table [2](#T2){ref-type="table"}. Figure [1](#F1){ref-type="fig"} reports the chromatographic profiles obtained by analyzing the 10 selected steroids injecting 20 µL of the calibration 7 standard solution (see Table [S2](#SM4){ref-type="supplementary-material"} in Supplementary Material). Aldosterone and Cortisol are the only co-eluting steroids. Their retention time is 5.56 min. However, they are discriminated based on of their *m*/*z* parent ion difference (*m*/*z* 359.2 for aldosterone and *m*/*z* 363.1 for cortisol) and selective MRM transition (*m*/*z* 359.2---\>189.1 and 359.2---\>331.3 for aldosterone; *m*/*z* 363.1---\>121, and 363.1---\>115.1 for cortisol). DHEA and DHEAS exhibit the same parent ion, due to the fact that DHEAS loses its sulfate groups in the source. The discrimination between the two compounds occurs on the basis of LC retention time (9.30 min for DHEA and 6.89 min for DHEAS).

###### 

Table reporting the mass spectrometry (MS)/MS MRM analyte transitions.

  Steroids               Parent ion   Fragment ion
  ---------------------- ------------ --------------
  Aldosterone 1          359.2        189.1
  Aldosterone 2          359.2        331.3
  Corticosterone 1       347.1        121.1
  Corticosterone 2       347.1        97.1
  Cortisol 1             363.1        115.1
  Cortisol 2             363.1        121
  11-deoxycortisol 1     347.11       97
  11-deoxycortisol 2     347.11       109
  Androstenedione 1      287.1        97
  Androstenedione 2      287.1        109
  Testosterone 1         289.1        97
  Testosterone 2         289.1        109
  DHEA 1                 271.2        213.1
  DHEA 2                 271.2        253.2
  DHEAS 1                271.2        197.1
  DHEAS 2                271.2        213.2
  17-OH-Progesterone 1   331          97
  17-OH-Progesterone 2   331          109
  Progesterone 1         315.1        97
  Progesterone 2         315.1        109

![Liquid chromatographic (LC) profiles obtained using the standards for the 10 selected steroids (20 µL) that were subjected to mass spectrometry (MS)/MS-MRM. Only two of the analytes eluted at the same time, but these were easily distinguished by the MS/MS-MRM.](fendo-09-00110-g001){#F1}

Stability and performance of the method mainly in terms of matrix effect, LOD, LOQ, and linearity range were tested. Matrix effect was evaluated both based on internal standards stability and on precision and accuracy parameters (Table [3](#T3){ref-type="table"}). Internal standard inter-analysis variation was lower than 5% while intra-day precision and accuracy error were lower than 6 and 8%, respectively. Even interday data show good reproducibility with precision and accuracy error lower than 8 and 9%, respectively. Table [3](#T3){ref-type="table"} reports also the LOD, LOQ, and linearity range for each analyte. The LOD are among 0.01 and 1 ng/mL depending by the analytes while LOQ among 0.05 and 5 ng/mL. Linearity range covers four orders of magnitude for each analyte.

###### 

Precision and accuracy error %, limit of detection (LOD), limit of quantitation (LOQ), and linearity range for each steroid.

  Steroids                         IS % Variation %   Intraday precision %   Intraday accuracy %   Interday precision %   Interaday accuracy %   LOD    LOQ    Linearity range
  -------------------------------- ------------------ ---------------------- --------------------- ---------------------- ---------------------- ------ ------ -----------------
  11-deoxycortisol                 4                  5                      7                     7                      8                      0.01   0.05   0.05--1,000
  17-OH-progesterone               3                  5                      6                     6                      8                      0.01   0.05   0.05--1,000
  Aldosterone                      3                  3                      6                     7                      8                      0.02   0.05   0.05--1,000
  Andro-stenedione                 4                  4                      7                     7                      8                      0.05   0.1    0.1--2,000
  Corticosterone                   4                  4                      5                     6                      7                      0.05   0.1    0.1--2,000
  Cortisol                         3                  3                      4                     6                      7                      1      5      5--7,000
  Dehydroepiandrosterone           3                  5                      6                     7                      8                      0.1    1      1--5,000
  Dehydroepiandrosterone sulfate   4                  5                      7                     7                      7                      1      10     10--7,000
  Progesterone                     3                  4                      7                     6                      7                      0.01   0.05   0.05--1,000
  Testosterone                     3                  5                      6                     7                      8                      0.01   0.05   0.05--1,000

After verifying the method stability, patient samples were analyzed. The absolute quantitation values for each steroid are reported in Table [S2](#SM4){ref-type="supplementary-material"} in Supplementary Material together with the quantitation curves. The steroids concentrations are in different ranges based on the analyzed molecules, which are given for each patient in Table [S2](#SM4){ref-type="supplementary-material"} in Supplementary Material. In particular, 11-deoxycortisol, 17-Oh-progesterone, aldosterone, androstenedione, corticosterone, DHEA, progesterone, testosterone concentration is under 50 ng/mL, while DHEAS and cortisol are much higher, in some cases can be over 1,000 ng/mL.

Since the PSA levels were used to determine the control group, this would introduce a bias into the system for determining the performance of PSA. Using PSA for the BPH and the PCa patients, the PSA receiver-operating characteristic (ROC) curve was calculated and area under the curve was 0.7118. We determined a threshold based on the lower limit of the 95 confidence intervals of the geometric mean of the PSA of the PCa patients, lead to a sensitivity (true positives) of 63% and specificity (true negatives) of 59%. The PSA, Gleason score, and AR receptor data of the cancer patients, benign prostate hypertrophy and control subjects are reported in Table [1](#T1){ref-type="table"}A--C, respectively.

Most of the steroids were lower in the PCa patients than in the controls (both healthy and BPH) and are shown graphically in Figure [2](#F2){ref-type="fig"}. This is in keeping with the lower levels of free testosterone that are associated with "progression" or "reclassification" of PCa ([@B9], [@B11]). However, these data do not coincide with the lower levels of free testosterone in patients with BPH ([@B8], [@B10]) and the inflammatory state with the lack of AR in luminal cells in murine models ([@B14]). These studies used RIA conditions, which could affect the level of accuracy. Since more and more clinical studies will be using LC/MS-MS for analyzing androgen levels, our data will be possibly confirmed. Both the enzymes that synthesize androgens ([@B40], [@B41]) and the breakdown of androgens ([@B42], [@B43]) are present in PCa cells and may affect circulating androgen and steroid levels.

![**(A)** Classic analysis of absolute concentrations of the steroids. **(B)** Receiver-operating characteristic (ROC) curve of dehydroepiandrosterone sulfate based on the classification in Table [1](#T1){ref-type="table"}. **(C)** Analysis of the output of the machine learning (based on the classification in Table [1](#T1){ref-type="table"}) and ROC of the values obtained (\**p* \< 0.05; \*\**p* \< 0.01; *p* \< 0.001 one way ANOVA, Graphpad Prism 5).](fendo-09-00110-g002){#F2}

There were several statistically significant differences between the hormones that separated the patients with prostate carcinoma versus those of benign prostate hyperplasia and controls. The only hormonal value separating statistically all three cases was the one of DHEAS. We determined a threshold based on the upper limit of the 95 confidence intervals of the geometric mean of the DHEAS of the PCa patients (Table [1](#T1){ref-type="table"}). This identified 11/20 (55%) of the PCa patients, 16/20 (80%) of the BPH patients, and 19/31 (62%) of the healthy controls. The ROC curve was calculated and area under the curve (separating the PCa from BPH and HC) was 0.702 (Figure [2](#F2){ref-type="fig"}). The sensitivity was 55% and the specificity was 59%. We also performed a Principal Component Analysis (PCA) ([@B44]) on the steroid absolute values (Figure [3](#F3){ref-type="fig"}). PCA is a method where a multivariate data set is linearly transformed into a set of uncorrelated variables that are ordered in descending manner, the first few components that often explain large amount of the variation ([@B44]). BPH patients and controls overlapped extensively (Figure [3](#F3){ref-type="fig"}). The vast majority of the PCa patients (Figure [3](#F3){ref-type="fig"}) were grouped into a restricted subset of the area of the BPH patients and controls.

![Principal component analysis (PCA) of the absolute (normalized) concentrations of all the steroids. Points labeled in red are PCa patients, in blue are the benign prostate hypertrophy patients, green are the healthy controls. Principal component (PC) 1 and PC 2 explain 34.4 and 18.5% of the total variance, respectively. The prediction ellipses are such that with a probability 0.95, a new observation from the same group will fall inside the ellipse.](fendo-09-00110-g003){#F3}

We then proceeded in calculating the comparison vector employed to build the progressively updated supervised database that will be used for sample classification on the basis of individual steroid enzymatic profiles. When similarity vectors are calculated following the SANIST algorithm ([@B39]), the cortisol and DHEAS exhibits a high weight on the calculation function and the other concentration parameters area weakly considered by the discrimination function. To avoid this problem, we "normalized" the weight of the cortisol and DHEAS by dividing their value by 10 and 100, respectively. All the samples were subjected to this normalization model.

The database vectors are matched with the vectors of unclassified samples in order to obtain a diagnosis. The algorithm then provides for each subject the steroid ratio relationships with respect to the others, and a complex relational map is obtained by using this approach (Figure [4](#F4){ref-type="fig"}). The discriminating power is not given by the position of the nodes but from the density of their relationships that is measured in a normalized scale between 1 and 100.

![Vector diagram of the steroid ratio relationships.](fendo-09-00110-g004){#F4}

Two database search profile match models were employed to predict the sample classification as control, PCa, or benign prostate hyperplasia. A cartoon of the classical approach and the ratio approach used in the matches are shown in Figure [S2](#SM2){ref-type="supplementary-material"} in Supplementary Material. In the case of steroid ratio concentration match, the angular difference among the vectors depends on the steroid concentration ratios, in the case of singular absolute concentration, it is correlated with the absolute concentration only.

We excluded each one of the samples and the learning machine used the other samples as a database to obtain the vectors. Then the sample that was excluded was categorized based on the vectors produced (Table [1](#T1){ref-type="table"}). The average output of this learning machine is given in Table [1](#T1){ref-type="table"}. There is a clear and significant separation of the PCa (18/20, 90%, all the false negatives were classified as HC), BPH (16/20, 80%, false positives were all PCa), and HC (25/31, 81%, false positives were all PCa) groups (Table [1](#T1){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). The ROC curves were calculated from these data and the area under the curve (again separating the PCa patients from BPH and HC) was 0.8353. The better performance was obtained using the steroid ratio relationship match model exhibiting a sensitivity of 90% and a specificity of 84%. In the case of singular absolute concentration match model the sensitivity (51%) and specificity (52%) are lower. There was no correlation with Gleason score or AR receptor status of any of the classification methods.

Another important information available through the steroid ratio concentration match model is that related to the couple of steroids that could lead to the enzyme classification. It is possible to extrapolate that by minimizing the Geometric Chebyshev distance by means of the SANIST technology ([@B35], [@B39]) and considering a ratio relational coefficient higher than 40 in relative value. Therefore, it is possible to correlate the altered steroids concentration ratios with the biological pathways and consequently with the enzyme potentially responsible for the disease. For example, Table [S3](#SM5){ref-type="supplementary-material"} in Supplementary Material shows two steroid relationship ratios that can selectively discriminate patients with prostate carcinoma from benign prostate hyperplasia and healthy controls, together with the associated enzyme (P450C17). This fact opens a way to a future prospective in personalized medicine applications that will provide detailed information to the clinical specialist together with the enzymes that can be targets of certain drugs. This information makes it possible to formulate personalized therapies that re-equilibrate the biochemical disequilibrium. To enrich database with the most relevant individual enzymatic pathways to be correlated with the cancer development and progression, an extensive multi-center study on more subjects is necessary and will be the target of future works.

Conclusion {#S4}
==========

Here, we provide a method for quantifying accurately 10 steroids in serum and calculate their ratios. We noted that the levels in the serum of PCa patients were lower than that of BPH and healthy controls, in particular testosterone. Based on clinical and experimental data ([@B8]--[@B11], [@B14]), this would imply that supplementation of testosterone in aged men might not be harmful. We also provide a novel SANIST data elaboration application to elaborate steroid profile data in PCa patients and to correlate them with known disease in a learning machine approach. It is based on the evaluation of steroids ratio relationships instead of the simple absolute concentrations. Steroids ratio relationships performed better (sensitivity 90%, specificity 84%) than PSA (sensitivity 63%, specificity 59%) or individual steroids concentrations (sensitivity 51%, specificity 52%). Our study has one limitations, a small sample size. However, it opens a new way to provide to the clinic a diagnostic hypothesis based on metabolic profile together with the steroid concentrations and their ratio relationships that eventually indirectly indicate the enzymes involved in endocrine and metabolic disorders.
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The calibrate analyte concentrations and the calculated concentrations of both known and unknown samples.
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Two steroid relationship ratios that can selectively discriminate patients with prostate carcinoma from benign prostate hyperplasia and healthy controls, together with the associated enzyme (P450C17).
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